<h3>Background</h3> Biological therapy is a major therapeutic tool to prevent clinical and radiological progression of rheumatoid arthritis (RA). On the other hand, adverse effects of these medications are a problem in clinical practice. <h3>Objectives</h3> The aim of this study was to describe and compare the most frequent dermatologic adverse events with the use of biologic therapy in patients with RA in a real-life ambulatory setting. <h3>Methods</h3> A descriptive study was done. A review of dermatological adverse event reports presented in pharmacovigilance committee was completed monthly during last 45 months in a specialized in RA center in Colombia. Descriptive epidemiology was used, percentages and averages were calculated. <h3>Results</h3> 680 patients were using biological therapy in a cohort of 2905 RA patients last 45 months; 579 women (85.2%) and 101 (14.8%) men. Mean age 60.3 years old. In 153 (22.5% of all patients who received biologics) patients were reported dermatologic adverse events (AE); AE were categorized according WHO classification in mild, moderate and severe; between them 53 (34.6%) were mild, 88 (57.5%) were moderate and 12 (7.8%) were severe. From 153 events reported, only 3 (1.9%) needed a biopsy to clarify what type of dermatologic reaction presented. Regarding therapeutic approach in 54 patients (35.2%) biologics were temporally suspended, in 21 (13.7%) was permanently withdrawn, 27 patients (17.6%) were switched to another biological, and 51 (33.3%) patients were followed for drug and reactions surveillance. From 153 events reported, 11 (7.1%) were acute dermatitis, 51 (33.3%) were dermatologic symptoms due to allergic skin rashes, 20 (13.1%) infection by Herpes zoster, 24 (15.6%) were dermatologic symptoms due to infection causes and the other 47 cases (30.7%) were due to other causes. Concerning to type of biologic, in 124 patients (81.0%) dermatologic adverse events were with anti-TNF therapies. <h3>Conclusions</h3> Dermatological adverse events using biologics are observed in a fifth of patients from a specialized RA center and are similar to those reported in literature; Biological therapy is considered a safe and recommended treatment for management of RA. Dermatologic AE were more mostly common with anti-TNFs subcutaneous therapies. <h3>Disclosure of Interest</h3> None declared